The structural integrity of an organism is the basis for its survival. To ensure structural integrity, protein synthesis is of vital importance. Protein synthesis is required both before and during cell division. Thus, Ace Therapeutics provides drug development services targeting the H. pylori protein synthesis mechanism in order to treat H. pylori infections from affecting the synthesis of proteins. And we offer drug development services targeting glutamate racemase, peptide deformylase, and dihydropteroate synthase.
Development of drugs targeting glutamate racemase of H. pylori
Glutamate racemase has an important role in the protein synthesis of peptidoglycan in H. pylori. H. pylori relies on peptidoglycan for protection against osmotic rupture and gastric proteolysis. And H. pylori requires glutamate racemase to convert L-glutamate to D-glutamate for synthesizing peptidoglycan. This means that glutamate racemase is important for the survival of H. pylori.
In this light, we provide drug development services targeting glutamate racemase. In addition, H. pylori's glutamate racemase possesses a unique cryptic isomer pocket compared to other bacterial glutamate racemases, and we develop unique drugs based on this cryptic isomer pocket for the targeted treatment of H. pylori infection.
Development of drugs targeting peptide deformylase
The peptide deformylase is essential for the synthesis of H. pylori proteins while it is not essential for human protein synthesis. H. pylori requires peptide deformylase to remove the formyl group from the N-terminal of the nascent peptide chains, which plays a crucial role in peptide chain elongation and is essential for the survival of H. pylori.
Fig. 1 Crystallographic tertiary structure of H. pylori peptide deformylase (Muhammad et al., 2016).
As peptide deformylase is an important drug target for the treatment of H. pylori infection, we provide drug development of substrate analogs, xenobiotic inhibitors, and macromolecular inhibitors of peptide deformylase with full consideration of the tertiary structure of peptide deformylase.
Development of drugs targeting dihydropteroate synthase
Folate analogs are important cofactors for the synthesis of essential amino acids and nitrogen bases. Humans take folate from the diet through the folate transporter protein while bacteria such as H. pylori do not have a folate transporter protein. And therefore H. pylori needs to synthesize folate de novo.
We thus offer to develop drugs based on blocking the synthesis of folate analogs to affect the synthesis of amino acids and nitrogen bases which are required for protein synthesis. As dihydropteroate synthase is essential for folate synthesis, we offer drug development services targeting dihydropteroate synthase of H. pylori.
Contact us
Ace Therapeutics provides drug development services targeting the H. pylori protein synthesis mechanism to help develop H. pylori therapeutics from a perspective that affects H. pylori survival. We offer drug development services targeting enzymes that affect the synthesis of protein, such as glutamate racemase, peptide deformylase, and dihydropteroate synthase. Please contact us if you have other needs.
References
- Chheda, P. R.; et al. Decrypting a cryptic allosteric pocket in H. pylori glutamate racemase. Communications Chemistry. 2021, 4(1): 172.
- Dawood, M.; et al. Molecular docking studies of sesquiterpenoids against Helicobacter pylori c. Br. J. Pharm. Res. 2016, 10(3): 1-7.
- Satuluri, S. H.; et al. Novel and potent inhibitors for dihydropteroate synthase of Helicobacter pylori. Journal of Receptors and Signal Transduction. 2020, 40(3): 246-56.
※ All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
